Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VAXiGEN's foot-and-mouth disease (FMD) vaccine is a veterinary vaccine candidate currently in the research and preclinical stages of development. It utilizes a proprietary 'Surface Display' platform technology, which involves presenting Foot-and-Mouth Disease Virus (FMDV) antigens on the surface of a carrier to effectively stimulate the host's immune system. The vaccine is designed to provide protection against FMD, a highly contagious viral disease affecting cloven-hoofed animals such as cattle, pigs, and sheep. VAXiGEN, the developer, is an Indian biotechnology company focused on creating indigenous vaccines for both human and animal health using mRNA and surface display technologies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VAXiGEN foot-and-mouth disease vaccine.